Intravenous Esketamine

Phase 3

UUniversity of Sao Paulo

Intravenous Esketamine is one of 13 therapeutic programs targeting Suicide. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

SuicideRecruiting

SuicidePhase 3

Recruiting

Competition

Competitive Landscape

13 competitors in Suicide

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

6 2

Estrace

Suboxone

2 4

Spravato

WWim Janssens

Approved

2 5

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Approved

1 7

Zyprexa

MMODAG GmbH

Approved

1 8

Ketalar

Boehringer Ingelheim

Phase 2

1 9

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 10

D-Cycloserine

MMassachusetts General Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

ApprovedRecruiting

Suicide

NCT07120477

Clinical

Trials by Indication[1]

Suicide1 trial

Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)

Recruiting·UUniversity of Sao Paulo·Approved·NCT07120477·478 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous Esketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intravenous Esketamine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Sao Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Sao Paulo

Intravenous Esketamine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Suicide1 trial

References

Drug Info

Quick Facts

Related News